EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access · CC BY-NC 4.0

A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial

Na Li, Zhixin Yang, Quan Yuan, Wenli Cheng iD

The Journal of Clinical Hypertension · 2025

DOI: 10.1111/jch.70098 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift The Journal of Clinical Hypertension, 2025. Verfasst von Na Li und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Health Care (Geriatrics), China-Japan Friendship Hospital, Ministry of Health, Beijing, China. Hauptthemen laut MEDLINE: Hypertension, Antihypertensive Agents, Blood Pressure. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Capital Health Development Scientific Research Project, Research Center for the development of Medical Science and Technology, National Health Commission of the People's Republic of China.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Current hypertension guidelines lack personalized strategies for blood pressure control. While the Systolic Blood Pressure Intervention Trial (SPRINT) demonstrated benefits of intensive blood pressure lowering, identifying optimal candidates for such treatment remains challenging. We developed and validated a risk stratification model using data from 9139 SPRINT participants. The model incorporated 11 clinical variables through multivariable Cox regression analysis. Patients were stratified into low‐, medium‐, and high‐risk groups. The study protocol was registered at ClinicalTrials.gov (NCT01206062). The model showed good discrimination with C‐indices of 0.7354 (95% CI: 0.7065–0.7710) and 0.6894 (95% CI: 0.6545–0.7266) at 3 years for training and validation sets, respectively. Intensive treatment significantly reduced cardiovascular events in medium‐risk (3.17% vs. 5.11%, p = 0.0376) and high‐risk groups (9.34% vs. 11.86%, p = 0.0269), while showing a nonsignificant trend in the low‐risk group (2.87% vs. 3.34%, p = 0.0870). The Rank‐Weighted Average Treatment Effect analysis (16.06) supported potential benefits from individualized treatment allocation. No increased risk of severe adverse events was observed across risk groups. Our risk stratification model effectively identifies patients who derive significant cardiovascular benefits from intensive blood pressure lowering, particularly in medium‐ and high‐risk groups. This approach could guide more personalized hypertension management strategies.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HypertensionAntihypertensive AgentsBlood PressureHumansFemaleMaleRisk AssessmentMiddle AgedAgedRisk FactorsCardiovascular DiseasesBlood Pressure DeterminationProportional Hazards Models

Stichwörter der Autor:innen

SPRINT trialblood pressure controlhypertension managementpersonalized medicinerisk stratification

Substanzen

Antihypertensive Agents

Autor:innen und Institutionen

  • Department of Health Care (Geriatrics), China-Japan Friendship Hospital, Ministry of Health, Beijing, China.
  • Department of Mathematical Sciences, Ball State University, Muncie, Indiana, USA.
  • Department of Information System and Operations Management, Ball State University, Muncie, Indiana, USA.
  • Centre of Hypertension, Beijing Anzhen Hospital, Capital Medical University, Beijing, China.

ORCID-Profile: Wenli Cheng

Förderung

  • Capital Health Development Scientific Research Project
  • Research Center for the development of Medical Science and Technology
  • National Health Commission of the People's Republic of China

Zitieren

APA

Li, N., Yang, Z., Yuan, Q., & Cheng, W. (2025). A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial. The Journal of Clinical Hypertension. https://doi.org/10.1111/jch.70098

Vancouver

Li N, Yang Z, Yuan Q, Cheng W. A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial. The Journal of Clinical Hypertension. 2025. doi:10.1111/jch.70098

BibTeX
@article{Li2025,
  author = {Li, Na and Yang, Zhixin and Yuan, Quan and Cheng, Wenli},
  title = {A Risk Stratification Model for Predicting Benefits of Intensive Blood Pressure Treatment: Analysis of the Systolic Blood Pressure Intervention Trial},
  journal = {The Journal of Clinical Hypertension},
  year = {2025},
  doi = {10.1111/jch.70098}
}
Kostenlos starten →